A Phase 2 Study of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Mati Therapeutics

Status and phase: Withdrawn; Phase 2

Conditions: Glaucoma; Ocular Hypertension

Treatments: Drug: Latanoprost-PPDS

Study type: Interventional

Funder types: Industry

Identifiers

NCT00855517

PPL GLAU 06

Details and patient eligibility

About

The purpose of this study is to evaluate IOP response to experimental dose of Latanoprost- PPDS in subjects with ocular hypertension or open-angle glaucoma.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Over 18 yrs of age with ocular hypertension or open-angle glaucoma
• Subjects who have a best corrected visual acuity of 20/100 or better

Exclusion criteria

• Subjects who wear contact lenses.
• Uncontrolled medical conditions
• Subjects requiring chronic topical artifical tears, lubricants and/or requiring any other chronic topical medications
• Subjects who have a history of chronic or recurrent inflammatory eye disease

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Punctal Plug

Experimental group

Treatment:

Drug: Latanoprost-PPDS